The company said its Q1 2024 revenues declined to $4.6 billion, down 1% as reported, and were approximately flat on an Organic basis year-over-year. It said decreased volume was partially offset by higher price.

1. 01

   The company said its Q1 2024 revenues declined to $4.6 billion, down 1% as reported, and were approximately flat on an Organic basis year-over-year. It said decreased volume was partially offset by higher price.

2. 02

   Net income margin for Q1 was 8.0%, up 10 basis points from 7.9% a year earlier, and Adjusted EBIT margin was 14.7%, up 50 basis points from 14.1%, the company said. It added that both measures benefited from productivity and price.

3. 03

   Cash flow from operating activities for Q1 was $419 million, down $49 million year over year, and free cash flow was $274 million, down $51 million, the company said. GE HealthCare also said it repaid $150 million of debt in January 2024.

4. 04

   GE HealthCare reaffirmed its full-year 2024 guidance, calling for Organic revenue growth of approximately 4%, Adjusted EBIT margin of 15.6% to 15.9%, Adjusted EPS of $4.20 to $4.35, and free cash flow of approximately $1.8 billion.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.